Key Findings: Micro and Nano Technologies for Point-of-Care Testing

• Publication date: October 2012
• Report size: 20 pages

Micro and nanotechnologies are set to transform point-of-care diagnostics. Miniaturization of testing methods, advances in lab-on-a-chip microfluidic methodologies, improvements in detection technologies and novel biosensors are leading the way.Identify micro and nanotechnologies driving the development of next-generation point-of-care diagnostics to benefit from...

Micro and nanotechnologies are set to transform point-of-care diagnostics. Miniaturization of testing methods, advances in lab-on-a-chip microfluidic methodologies, improvements in detection technologies and novel biosensors are leading the way.Identify micro and nanotechnologies driving the development of next-generation point-of-care diagnostics to benefit from opportunities being created.Discover which analytes/diseases are currently being targeted by profiled companies to formulate your own diagnostic product development strategies.Assess the evolving POC testing market with the aid of market forecasts for individual market segments to prepare for future growth in this area.Forecast key point-of-care testing market segments to 2016.Various proprietary technologies identified in this report underpin POC testing products in development. These technologies represent valid alternative approaches to challenges such as multiplexing, liquid transport in miniaturized systems, integration of assay procedures, and limitations associated with the use of traditional fluorescent labels.The microfluidic lab-on-a-chip (LoC) is now firmly established as an attractive miniaturized platform for POC testing. Maturing of LoC technologies is stimulating efforts to incorporate miniaturized biosensors into portable LoC systems to accelerate the development of portable and handheld testing systemsMost of the products discussed in this report are being developed for healthcare professional-based testing. Four professional-based POCT market sectors - infectious disease; cardiac marker; coagulation (including pharmacogenomics); and cancer screening/pharmacogenomics - are forecast to grow at CAGRs of 14%, 22%, 19% and 30% respectively.Which micro and nano technologies in development offer the attributes of miniaturization, fast readout time, multiplexing, and cost-effectiveness?What drivers and restraints operate in the nascent market for POC testing products based on micro and nanotechnologies?Who is developing new POC testing products based on micro and nanotechnologies and which clinical applications are they targeting?How will POC testing products based on micro and nanotechnologies impact areas inadequately served by current products and areas of unmet need?What are the estimated current market sizes and 5-year growth forecasts for the sectors of the POC testing market currently targeted?

In Vitro Diagnostic Industry in the United Kingdom

About this report
•Overview
•Contributors - (Untitled sub-section)

•Methodology
•Current POCT technologies and applications - Enabling IVDT technologies
- Current POCT systems
- Regulation of IVDs

•Micro- and nanotechnologies for POCT - Microarrays
- Nanoarrays

•Microfluidics?based LoC systems - Integrated LoC commercial systems
- Immobilization methods for immunoassays
- Liquid transport control strategies
- Detection methods

•Advances in biosensors - Optical detection
- Electrochemical sensors
- Other emerging sensor technologies

•Company activity
•Market trends and forecasts - Characteristics of the IVD industry
- Therapeutic opportunities for POCT



APPENDIX


•Disclaimer


TABLES


•Table: Global POCT market forecasts by reviewed segment, 2011–16


FIGURES


•Figure: A typical lab-on-a-chip for POC testing with associated instrumentation


Companies Mentioned

Abbott Laboratories, Cepheid, GlaxoSmithKline Plc, Hutchison 3G UK Limited, Informa plc